ТРАНСПЛАНТАЦИЯ ПЕЧЕНИ И HBV-ИНФЕКЦИЯ
https://doi.org/10.15825/1995-1191-2009-4-110-117
Аннотация
В статье представлены современные данные по трансплантации печени при HBV-инфекции. Показано, что пациенты с циррозом печени HBV-этиологии, ожидающие трансплантации печени, должны длитель- но получать аналоги нуклеоз(т)идов вплоть до ОТП. Обсуждаются различные схемы профилактики воз- вратной HBV-инфекции в посттрансплантационном периоде и специфическое лечение de novo гепатита В после ОТП, возможность выполнения ОТП пациентам с ГЦР в исходе цирроза печени HBV-этиологии.
Об авторах
О. И. Андрейцева
НИИ СП им. Н.В. Склифосовского, Москва
Россия
Россия
А. В. Козлова
НИИ СП им. Н.В. Склифосовского, Москва
Россия
Россия
В. Е. Сюткин
НИИ СП им. Н.В. Склифосовского, Москва
Россия
Россия
Список литературы
1. Шерлок Ш., Дули Д. Рецидив болезни // Заболевания пе- чени и желчных путей. М.: ГЭОТАР Медицина, 1999. С. 756.
2. Angelico M., Di Paolo D., Trinito M.O. et al. Failure of a reinforced triple course of hepatitis B vaccination in pa- tients transplanted for HBV-related cirrhosis // Hepatology. 2002. Vol. 35. P. 176–181.
3. Angus P.W., McCaughan G.W., Gane E.J. et al. Combina- tion low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttrans- plantation hepatitis B // Liver Transpl. 2000. Vol. 6. P. 429– 433.
4. Angus P.W., Patterson S.J., Strasser S.I. et al. A randomized study of adefovir dipivoxil in place of HBIG in combina- tion with lamivudine as post-liver transplantation hepatitis B prophylaxis // Hepatology. 2008. Vol. 48. P. 1460–1466.
5. Barcena R., Moraleda G., Moreno J. et al. Prevention of de novo HBV infection by the presence of anti-HBs in trans- planted patients receiving core antibody-positive livers // World J. Gastroenterol. 2006. Vol. 7; 12 (13). P. 2070– 2074.
6. Buti M., Mas A., Prieto M. et al. A randomized study com- paring lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepa- titis B virus recurrence after liver transplantation // J. Hepa- tol. 2003. Vol. 38. P. 811–817.
7. Cahlin C., Olausson M., Friman S. Severe clinical course of de novo hepatitis B infection after liver transplantation // Transplant. Proc. 2001. Vol. 33 (4). P. 2467–2468.
8. Castells L., Esteban R. Hepatitis B vaccination in liver transplant candidates // Eur. J. Gastroenterol. Hepatol. 2001. Vol. 13 (4). P. 359–361.
9. Castells L., Vargas V., Rodríguez F. et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation // Liver Transpl. 2002. Vol. 8 (10). P. 892–900.
10. Chazouilleres O., Mamish D., Kim M. et al. «Occult» hepa- titis B virus as source of infection in liver transplant reci- pients // Lancet. 1994. Vol. 343 (8890). P. 142–146.
11. Crespo J., Fábrega E., Casafont F. et al. Severe clinical course of de novo hepatitis B infection after liver trans- plantation // Liver Transpl. Surg. 1999. No 5 (3). P .175– 183.
12. Degertekin B., Lok A.F. Hepatocellular Carcinoma (HCC) is the main Indication for Liver Transplantation (OLT) among HBV Patients in the era of Nucleos/tide Analogue Therapies, 59th AASLD Meeting, October 31-November 4, 2008, San Francisco, USA // Hepatology. 2008; 48 (abstract 1437).
13. Dickson R.C., Everhart J.E., Lake J.R. et al. Transmission of hepatitis B by transplantation of livers from donors posi- tive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database // Gastroenterology. 1997. Vol. 113 (5). P. 1668–1674.
14. Dodson S.F., de Vera M.E., Bonham C.A. et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation // Liver Transpl. 2000. Vol. 6. P. 434–439.
15. Douglas D.D., Rakela J., Taswell H. et al. Transmission of hepatitis B virus infection from orthtopic donor livers [ab- stract] // Hepatology. 1992. Vol. 16. P. 49A.
16. Douglas D.D., Rakela J., Wright T.L. et al. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient // Liver Transpl. Surg. 1997. Vol. 3 (2). P. 105–111.
17. Fabia R., Levy M., Crippin J. et al. De novo hepatitis B infection after liver transplantation: sources of disease, in- cidence and impact // Liver. Transpl. Surg. 1997. Vol. 4. P. 119–127.
18. Gane E.J., Angus P.W., Strasser S. et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation // Gastroentero- logy. 2007. Vol. 132. P. 931–937.
19. Grellier L., Mutimer D., Ahmed M. et al. Lamivudine prop- hylaxis against reinfection in liver transplantation for hepa- titis В cirrhosis // Lancet. l996. Vol. 348. P. 1212–1215.
20. Hussain M., Soldevila-Pico C., Emre S. et al. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation // Liver Transpl. 2007. Vol. 13. P. 1137–1144.
21. Hwang S., Lee S.G., Ahn C.S. et al. Prevention of hepati- tis B recurrence after living donor liver transplantation: pri- mary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy // Liver Transpl. 2008. Vol. 14. P. 770–778.
22. Jiao Z.Y., Jiao Z. Prophylaxis of recurrent hepatitis B in Chinese patients after liver transplantation using lamivudi- ne combined with hepatitis B immune globulin according to the titer of antibody to hepatitis B surface antigen // Trans- plant. Proc. 2007. Vol. 39. P. 1533–1536.
23. Jiao Z.Y., Yan L.N., Li B. et al. Liver transplantation for chronic hepatitis B patients with lamivudine monotherapy or lamivudine combined with individualized low-dose he- patitis B immunoglobulin treatment // Zhonghua Ganzang- bing Zazhi. 2007. Vol. 15. P. 804–808.
24. Karademir S., Astarcioglu H., Akarsu M. et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B im- munoglobulin and lamivudine after liver transplantation // Transplant. Proc. 2006. Vol. 38. P. 579–583.
25. Kim K.K., Kim K.H., Hwang S. et al. Therapeutic effect of adefovir dipivoxil on recurrent or de novo infection of hepatitis B virus after liver transplantation: a preliminary report. Article in Korean // Korean. J. Gastroenterol. 2005. Vol. 45 (3). P. 174–180.
26. Lampertico P., Viganò M., Donato M. et al. Excellent 5-year overall survival in patients with HBV-related cirrhosis un- dergoing transplantation for hepatocellular carcinoma, 59th AASLD Meeting, October 31-November 4, 2008, San Fran- cisco, USA // Hepatology. 2008. Vol. 48 (abstract 621).
27. Lauchart W., Muller R., Pichlmayr R. Long-term immunopro- phylaxis of hepatitis B virus reinfection in recipients of human liver allografts // Transplant. Proc. 1987. Vol. 19. P. 4051–4053.
28. Li Jiang, Li-Sheng Jiang, Nan-Sheng Cheng and Lu-Nan Yan. Current prophylactic strategies against hepatitis B vi- rus recurrence after liver transplantation // World. J. Gas- troenterol. 2009 May 28. No 15 (20). Р. 2489–2499.
29. Limquiaco J.L., Wong J., Wong V.W. et al. Lamivudine mo- noprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study // J. Med. Virol. 2009. Vol. 81. Р. 224–229.
30. Lo C.M., Cheung S.T., Lai C.L. et al. Liver transplantation in Asian patients with chronic hepatitis В using lamivudine prophylaxis // Ann. Surg. 2001. Vol. 233. Р. 276–281.
31. Lok A.S., Heathcote E.J., Hoofnagle J.H. Management of hepatitis B: 2000 – summary of a workshop // Gastroenterology. 2001. Vol. 120. Р. 1828–1853.
32. Markowitz J.S., Martin P., Conrad A.J. et al. Prophylaxis against hepatitis B recurrence following liver transplanta- tion using combination lamivudine and hepatitis B immune globulin // Hepatology. 1998. Vol. 28. Р. 585–589.
33. McGory R.W., Ishitani M.B., Oliveira W.M. et al. Improved outcome of orthotopic liver transplantation for chronic he- patitis B cirrhosis with aggressive passive immunization // Transplantation. 1996. Vol. 61. Р. 1358–1364.
34. Mutimer D., Dusheiko G., Barrett C. et al. Lamivudine wit- hout HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up // Transplantation. 2000. Vol. 70. Р. 809–815.
35. Mutimer D., Pillay D., Dragon E. et al. High pre-treatment serum hepatitis В virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation // J. Hepatol. 1999. Vol. 30. Р. 715–721.
36. Nevin Yilmaz, Mitchell L. Shiffman, R. Todd Stravitz et al. Prophylaxis Against Recurrance of Hepatitis B Virus After Liver Transplantation: A Retrospective Analysis Spanning 20 Years // J. Liver International. January 2008. Vol. 28 (1). Р. 72–78.
37. Patterson S.J., Angus P.W. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues // Current opinion in organ transplantation. 2009. Vol. 14. Р. 225–230.
38. Pellicelli A.M., Barbaro G., Barbarini G. et al. Efficacy of Entecavir as rescue therapy in lamivudine-resistant patients with HBV liver cirrhosis and waiting for orthotopic liver transplantation, 59th AASLD Meeting, October 31 – No- vember 4, 2008, San Francisco, USA // Hepatology. 2008. Vol. 48: 4 (suppl.). Р. 701A (abstract 885).
39. Perrillo R.P., Wright T., Rakela J. et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy be- fore and after liver transplantation for chronic hepatitis B // Hepatology. 2001. Vol. 33. Р. 424–432.
40. Prieto M., Gomez M., Berenguer M. et al. De novo he- patitis B after liver transplantation from hepatitis B core antibody–positive donors in an area with high prevalence of anti-HBc positivity in the donor population // Liver Transpl. 2001. No 7. Р. 51–58.
41. Roche B., Samuel D., Gigou M. et al. De novo and apparent de novo hepatitis B virus infection after liver transplanta- tion // J. Hepatol. 1997. Vol. 26 (3). Р. 517–526.
42. Roque-Afonso A.M., Feray C., Samuel D. et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors // Gut. 2002. Vol. 50 (1). Р. 95–99.
43. Samuel D., Bismuth A., Mathieu D. et al. Passive immuno- prophylaxis after liver transplantation in HBs-Ag-positive patients // Lancet. 1991. Vol. 337. Р. 813–815.
44. Samuel D., Muller M., Alexander G. et al. Liver transplan- tation in European patients with the hepatitis B surface an- tigen // N. Engl. J. Med. 1993. Vol. 329. Р. 1842–1847.
45. Sanchez-Fueyo A., Rimola A., Grande L. et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation // He- patology. 2000. Vol. 31. Р. 496–501.
46. Seehofer D., Rayes N., Berg T. et al. Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation // Transpl. Int. 2000. Vol. 13. Р. 290–296.
47. Segovia R., Sanchez-Fueyo A., Rimola A. et al. Evidence of serious graft damage induced by de novo hepatitis B virus infection after liver transplantation // Liver Transpl. 2001. No 7. Р. 106–112.
48. Su W.J., Ho M.C., Ni Y.H. et al. High-titer antibody to he- patitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection // J. Pediatr. Gastroen- terol. Nutr. 2009. Vol. 48 (2). Р. 203–208.
49. Toniutto P., Fumo E., Caldato M. et al. Favourable outcome of adefovir-dipivoxil treatment in acute de novo hepatitis B after liver transplantation // Transplantation. 2004. Vol. 15; 77 (3). Р. 472–473.
50. Uemoto S., Sugiyama K., Marusawa H. et al. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants // Transplantation. 1998. Vol. 65 (4). Р. 494–499.
51. Umeda M., Marusawa H., Ueda M. et al. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation // Am. J. Trans- plant. 2006. Vol. 6 (11). Р. 2680–2685.
52. Villeneuve J.P., Condreay L.D., Willems B. et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B // Hepatology. 2000. Vol. 31. Р. 207–210.
53. Wachs M.E., Amend W.J., Ascher N.L. et al. The risk of transmission of hepatitis B from HBsAg(–), HBcAb(+), HBIgM(–) organ donors // Transplantation. 1995. Vol. 59 (2). Р. 230–234.
54. Yao F.Y., Bass N.M. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepati- tis В infection // J. Hepatоl. 2000. Vol. 33. Р. 301–307.
55. Yao F.Y., Terrault N.A., Freise C. et al. Lamivudine treat- ment is beneficial in patients with severely decompensa- ted cirrhosis and actively replicating hepatitis В infection awaiting liver transplantation: a comparative study using a matched, untreated cohor // Hepatology. 2001. Vol. 34. Р. 411–416.
56. Zheng S., Chen Y., Liang T. et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis // Liver Transpl. 2006. Vol. 12. Р. 253–258.
Рецензия
Для цитирования:
Андрейцева О.И., Козлова А.В., Сюткин В.Е. ТРАНСПЛАНТАЦИЯ ПЕЧЕНИ И HBV-ИНФЕКЦИЯ. Вестник трансплантологии и искусственных органов. 2009;11(4):110-117. https://doi.org/10.15825/1995-1191-2009-4-110-117
For citation:
Andreytseva O.I., Kozlova A.V., Sutkin V.E. LIVER TRANSPLANTATION AND HBV INFECTION. Russian Journal of Transplantology and Artificial Organs. 2009;11(4):110-117. (In Russ.) https://doi.org/10.15825/1995-1191-2009-4-110-117
Просмотров: 551
Послать статью по эл. почте 